

Quellen

1. Stein A, Lorenzen S, Stocker G et al. Real-world evidence in gastric and esophageal cancer: first results of patients treated with nivolumab + chemotherapy from the noninterventional INGA study in Germany. Präsentiert auf dem ESMO GI 2025, Barcelona, Spanien; Poster #453P.
2. Janjigian YY, Moehler M, Ajani JA, et al. Nivolumab plus chemotherapy vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649. ASCO GI 2025; Poster number 398.
3. Fachinformation Opdivo, aktueller Stand